- Oncolytic Viral Therapies & Cancer Vaccines
- Monoclonal Antibodies
- Immunomodulators
Cancer Immunotherapy Market size was valued at USD 120 billion in 2023. It is expected to reach a value of USD 304 billion by 2029, growing at a CAGR of 14.2% from 2024-2030. The global market provides a detailed overview of the cancer immunotherapy market and that can be segmented by product type and cancer type. By product type, the cancer immunotherapy market has been segmented into oncolytic viral therapies & cancer vaccines, monoclonal antibodies, and immunomodulators. The oncolytic viral therapies & cancer vaccines segment is likely to be the largest and fastest-growing segment in terms of product type. Based on cancer type, the cancer immunotherapy market is segmented into breast and lung. Among these, the breast segment is expected to have the fastest-growing market during the forecast period.
Cancer Immunotherapy Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
14.2%
Largest Market
North America
Fastest Growing Market
Asia-Pacific
Cancer Immunotherapy Market Dynamics
Some of the key factors boosting the market growth include rising spending on healthcare needs, a surge in cancer cases, increasing R&D efforts in the field of cancer immunotherapy, and increasing use of modern cancer therapy alternatives. Moreover, immunotherapy is becoming more popular and has strong growth potential in developing nations.
Asia Pacific Got Significant Share
Cancer Immunotherapy Market Regional Analysis
By region, the Asia Pacific market is expected to witness the highest market share during the forecast period due to an increase in healthcare spending, a rise in per capita income, and improvements to the healthcare system. North America held a considerable market share during the estimated period owing to an increase in the number of cancer patients, an increase in the use of immunotherapy, and the development of bioinformatics tools.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019 to 2023) and forecast (2024 to 2030)
- The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and startup's details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis in addition to recent technology advancements and innovations in the market
Cancer Immunotherapy Market Segmentation
By Product Type
By Cancer Type
- Breast
- Lung
By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Frequently Asked Questions
The cancer immunotherapy market size was valued at USD 120 billion in 2022
The major players in the global cancer immunotherapy market are Amgen, Inc., Astrazeneca, PLC, Bayer AG, Bristol-Myers Squibb Company, Eli Lily and Company, F. Hoffmann-La Roche, Ltd. (Genentech, Inc.), Pfizer, Inc., Johnson & Johnson (Janssen Global Services, LLC), Merck KGAA and Novartis AG.
Asia Pacific is the fastest-growing region for cancer immunotherapy market
| 1.Executive Summary |
| 2.Global Cancer Immunotherapy Market Introduction |
| 2.1.Global Cancer Immunotherapy Market - Taxonomy |
| 2.2.Global Cancer Immunotherapy Market - Definitions |
| 2.2.1. By Product Type |
| 2.2.2. By Cancer Type |
| 2.2.3. By Region |
| 3.Global Cancer Immunotherapy Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Cancer Immunotherapy Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Cancer Immunotherapy Market By Product Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Oncolytic Viral Therapies & Cancer Vaccines |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Monoclonal Antibodies |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Immunomodulators |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6.Global Cancer Immunotherapy Market By Cancer Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Breast |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Lung |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7.Global Cancer Immunotherapy Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.North America Cancer Immunotherapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Oncolytic Viral Therapies & Cancer Vaccines |
| 8.1.2.Monoclonal Antibodies |
| 8.1.3.Immunomodulators |
| 8.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Breast |
| 8.2.2.Lung |
| 8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9.Europe Cancer Immunotherapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Oncolytic Viral Therapies & Cancer Vaccines |
| 9.1.2.Monoclonal Antibodies |
| 9.1.3.Immunomodulators |
| 9.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Breast |
| 9.2.2.Lung |
| 9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 10.Asia Pacific (APAC) Cancer Immunotherapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Oncolytic Viral Therapies & Cancer Vaccines |
| 10.1.2.Monoclonal Antibodies |
| 10.1.3.Immunomodulators |
| 10.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Breast |
| 10.2.2.Lung |
| 10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11.Middle East and Africa (MEA) Cancer Immunotherapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Oncolytic Viral Therapies & Cancer Vaccines |
| 11.1.2.Monoclonal Antibodies |
| 11.1.3.Immunomodulators |
| 11.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Breast |
| 11.2.2.Lung |
| 11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12.Latin America Cancer Immunotherapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Oncolytic Viral Therapies & Cancer Vaccines |
| 12.1.2.Monoclonal Antibodies |
| 12.1.3.Immunomodulators |
| 12.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Breast |
| 12.2.2.Lung |
| 12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.Amgen, Inc |
| 13.2.2.Astrazeneca, PLC |
| 13.2.3.Bayer AG |
| 13.2.4.Bristol-Myers Squibb Company |
| 13.2.5.Eli Lily and Company |
| 13.2.6.Hoffmann-La Roche, Ltd. (Genentech, Inc.) |
| 13.2.7.Pfizer, Inc. |
| 13.2.8.Johnson & Johnson (Janssen Global Services, LLC) |
| 13.2.9.Merck KGAA |
| 13.2.10.Novartis AG |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
- Amgen, Inc
- Astrazeneca, PLC
- Bayer AG
- Bristol-Myers Squibb Company
- Eli Lily and Company
- Hoffmann-La Roche, Ltd. (Genentech, Inc.)
- Pfizer, Inc.
- Johnson & Johnson (Janssen Global Services, LLC)
- Merck KGAA
- Novartis AG